Teva Pharmaceuticals USA, Inc.
The Federal Circuit has resolved prior inconsistencies in its case law and established a bright line rule to define infringement in product-by-process claims, holding that such infringement requires practice of the claimed process by the alleged infringer. In Abbott Labs v. Sandoz, 566 F.3d 1282 (Fed. Cir. 2009), the Federal…
New Judicial Opinions
On summary judgment, the district court found in favor of plaintiffs Eisai Co., Ltd. and Eisai, Inc. (collectively “Eisai”) with respect to the validity and enforceability of 552 patent. Opinion, pp. 1-2, citing Eisai Co. v. Teva Pharms. USA, Inc., No. 03 Civ. 9223 (S.D.N.Y. Oct. 5, 2006); Eisai Co.…
Date of ruling: